Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 8/20 | 0.44 |
| ▸ | CTSB | P07858 | 8/20 | 0.44 |
| ▸ | CTSK | P43235 | 6/20 | 0.44 |
| ▸ | CTSL | P07711 | 5/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422146 | 0.89 | CTSS (0.52) | CTSSCTSBCTSKCTSLACE | |
| SCHEMBL5419962 | 0.82 | CYP1A2 (0.49) | CTSSCTSBCTSKCTSLACE | |
| SCHEMBL7544294 | 0.77 | CTSC (0.51) | CTSSCTSBCTSKCTSLACE | |
| SCHEMBL5414780 | 0.76 | CTSS (0.46) | FOLH1CTSSCTSBCTSKCTSL | |
| SCHEMBL7594265 | 0.76 | CTSB (0.55) | FOLH1CTSSCTSBCTSKCTSL | |
| SCHEMBL11231555 | 0.75 | EPHX1 (0.52) | FOLH1CTSBLMNAGLAEPHX1 | |
| SCHEMBL5426573 | 0.75 | CTSS (0.41) | CTSSCTSBCTSKCTSL | |
| SCHEMBL6742386 | 0.74 | CTSS (0.56) | CTSSCTSBCTSKCTSLACE | |
| SCHEMBL5524107 | 0.74 | CTSL (0.71) | CTSSCTSBCTSKCTSLCTSV | |
| SCHEMBL5524111 | 0.74 | CTSL (0.71) | CTSSCTSBCTSKCTSLCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | FOLH1 435/4885CTSS 1/4885CTSB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.